Fund moves

AbbVie (ABBV): Douglass Winthrop Advisors, LLC added to its stake +8,213 shares

Douglass Winthrop Advisors, LLC added to its stake in AbbVie, per its Q2 2026 13F.

61K
Shares reported · +8,213 vs prior quarter
0.27%
Disclosed portfolio weight
$15.4M
Reported value
Holdings as of
Jun 30, 2026
Filed
Aug 13, 2026

What stands out in this filing

  • 52,875 shares in Q1 2026, 61,088 now (+15.5% in share count).
  • Reported at $15.4M, 0.27% of the portfolio value in this 13F filing.
  • 121 other tracked managers reported the same kind of change for Q2 2026.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: reported its results, 13 days earlier (Jul 31, 2026). The first one after it: reported its results, 53 days later (Oct 5, 2026).

  1. CongressDisclosed purchase of ABBV — reported range $15,001 - $50,000
  2. Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.6K obligated to date
  3. FDAFDA drug approval: Skyrizi
  4. Government · Federal Register noticeDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  5. Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
  6. Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.3K obligated to date
  7. Company filing · Form 8-K · ResultsReported its results
  8. Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
  9. Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
  10. Company filing · Form 8-K · ResultsReported its results

What came next

  1. Insider · Their largest sale since 2023Officer sold ~$8.18M of ABBV shares in the open market
  2. Government · Federal Register noticeDetermination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  3. Government · Federal Register noticeDetermination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  4. CongressDisclosed sale of ABBV — reported range $15,001 - $50,000
  5. FDAFDA drug approval: Juvmo
  6. Company filing · Form 8-K · ResultsReported its results
  7. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director.”
  8. FDAFDA drug approval: Skyrizi
  9. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the result of any dispute or disagreement with AbbVie on any matter relating to…”
  10. Company filing · Form 8-K · ResultsReported its results
  11. Insider · Their largest sale since 2020Officer sold ~$11.9M of ABBV shares in the open market
  12. Government · Federal Register noticeDetermination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for AbbVie

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

How this filing works

Explore the data

Common questions

What does this filing report about AbbVie (ABBV) stock?

Douglass Winthrop Advisors, LLC added to its stake in AbbVie, per its Q2 2026 13F. Now 61K shares, $15.4M reported value, 0.27% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Jun 30, 2026. Filed: Aug 13, 2026.

What stands out in this filing?

52,875 shares in Q1 2026, 61,088 now (+15.5% in share count). Reported at $15.4M, 0.27% of the portfolio value in this 13F filing. 121 other tracked managers reported the same kind of change for Q2 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about AbbVie recently?

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.

Does this mean ABBV stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data